同步放化疗治疗非小细胞肺癌的临床分析

Clinical analysis of concurrent chemoradiation therapy treating non-small cell lung cancer

目的 探讨同步放化疗治疗非小细胞肺癌（NSCLC）的临床效果及毒副反应。方法 选择本院2011年1月～2013年1月收治入院的采用同步放化疗治疗的Ⅲ期NSCLC患者100例为观察组。另选择本院同期采用序贯放化疗治疗的Ⅲ期NSCLC患者100例为对照组，分析两组患者的治疗效果与毒副反应情况。结果 观察组中总有效55例，有效率为55．0％，对照组中总有效35例，有效率为35．0％，两组比较，差异有统计学意义（P〈0．05）；观察组的MST为10．3个月，对照组为9．6个月，两组比较，差异有统计学意义（P〈0．05）；不良反应主要为骨髓抑制、消化道反应（恶心、呕吐），经对症治疗后均能耐受而未终止治疗。两组的不良反应发生情况比较差异无统计学意义（P〉0．05）。结论 同步放化疗治疗Ⅲ期NSCLC的疗效优于序贯放化疗，不良反应增大但可耐受，值得进一步研究。

Objective To investigate the clinical effect and toxicity of concurrent chemoradiation therapy treating nonsmall cell lung cancer （NSCLC）. Methods 100 patients with NSCLC on stage IU from January 2011 to January 2013 given concurrent chemoradiation therapy were selected as the observation group,and another 100 cases given sequential chemoradiotherapy treatment at the same time were included in the control group.The treatment effect and toxicity of the two groups were compared. Results 55 cases in the observation group were effective,the total effective rate was 55.0%,35 cases in the control group were effective,the total effective rate was 35.0%,and there was a statistical difference between the two groups （P〈0.05）;the average median survival time （MST） were 10.3 months in the observation group and 9.6 months in the control group, with a significant difference （P〈0.05）;the main adverse reactions were myelosuppression,gastrointestinal symptoms （nausea,vomiting）.After symptomatic treatment,all patients could tolerate these adverse reactions without discontinuation of treatment.No significant difference was found between the two groups on the incidence of adverse reactions （P〉0.05）. Conclusion Concurrent chemoradiation is superior to sequential chemoradiotherapy for treating NSCLC on stage Ⅲ,the adverse reactions increases but tolerable.lt is worthy of further study.